Skip to Main Content

Tippi C. Mackenzie


Fetal and pediatric surgeon

Dr. Tippi MacKenzie is a pediatric surgeon with a special interest in fetal interventions. She is a member of the Biomedical Sciences Program and the director of the UCSF Broad Stem Cell Center, with a research focus on stem cell transplantation in utero to treat genetic diseases.

MacKenzie earned her medical degree at Stanford University School of Medicine and completed a residency in general surgery at Brigham and Women's Hospital. She completed a fellowship in pediatric surgery at the Children's Hospital of Philadelphia, where she held a clinical appointment in general, thoracic and fetal surgery.

  • Education

    Stanford School of Medicine, 1997

  • Residencies

    Brigham and Women's Hospital, Surgery, 1999

    Children's Hospital of Philadelphia, Pediatric Surgery, 2002

  • Fellowships

    Children's Hospital of Philadelphia, Pediatric Surgery, 2007

  • Board Certifications

    Surgery, American Board of Surgery

    Pediatric Surgery, American Board of Surgery

  • Academic Title


"What keeps me coming back to work every day is a desire to do better."

Where I see patients (1)

    My work

    Fetal therapy offers hope for treating genetic disorders

    An experimental therapy helped a family that had already lost two babies to a rare disorder with critical guidance from Dr. MacKenzie.

    Decorative Caduceus

    Registry of Patients Diagnosed With Lysosomal Storage Diseases

    Prenatal presentation of symptoms (e.g. hydrops) appearing on fetal imaging such as ultrasound and ECHO.


    Decorative Caduceus

    International Registry of Patients With Alpha Thalassemia

    Number of fetuses diagnosed with alpha thalassemia who survive to birth, compared to number of fetuses diagnosed with alpha thalassemia who have fetal demise or are terminated in utero. This is measured in number of fetuses alive ...


    Decorative Caduceus

    In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases

    Adverse and serious adverse events including, but not limited to, death within 24 hours after the procedure, stillbirth, death prior to initial hospital discharge,increased response with antibody development above that expected wi...